Alto Neuroscience Balance Sheet Health
Financial Health criteria checks 5/6
Alto Neuroscience has a total shareholder equity of $71.2M and total debt of $9.9M, which brings its debt-to-equity ratio to 13.9%. Its total assets and total liabilities are $86.6M and $15.5M respectively.
Key information
13.9%
Debt to equity ratio
US$9.86m
Debt
| Interest coverage ratio | n/a |
| Cash | US$82.55m |
| Equity | US$71.16m |
| Total liabilities | US$15.47m |
| Total assets | US$86.63m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: ANRO's short term assets ($85.4M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: ANRO's short term assets ($85.4M) exceed its long term liabilities ($9.9M).
Debt to Equity History and Analysis
Debt Level: ANRO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ANRO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANRO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 49% each year.